Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa PharmaceuticalsGlobeNewsWire • 08/16/23
Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular SurgeryPRNewsWire • 08/16/23
Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/10/23
Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual ConferenceGlobeNewsWire • 08/09/23
Eyenovia: Say Goodbye To The Eye Dropper And Welcome Optejet To The Market PlaceSeeking Alpha • 05/27/23
Eyenovia Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/11/23
Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company's Proprietary Optejet® Device PlatformGlobeNewsWire • 05/08/23
Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/30/23
Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30GlobeNewsWire • 03/23/23
Eyenovia Announces Development Collaboration Agreement with Formosa PharmaceuticalsGlobeNewsWire • 02/15/23
Formosa Pharmaceuticals Announces Development Collaboration Agreement with EyenoviaPRNewsWire • 02/15/23
Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to DropsGlobeNewsWire • 01/12/23
Eyenovia Announces Participation at the 2023 International Consumer Electronics ShowGlobeNewsWire • 12/20/22
Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil DilationGlobeNewsWire • 12/13/22